Literature DB >> 19138238

The effect of pre-hospital statins therapy on incidence of in-hospital death and total MACCE in patients with PCI.

M Zhang1, B Que, S-P Nie, J Kang, C-S Ma.   

Abstract

OBJECTIVE: To investigate the influence of preoperative statin therapy on rate of major adverse cardiac and cerebrovascular events (MACCE) during hospital stay after successful percutaneous coronary intervention (PCI).
METHODS: Review of patients who underwent PCI between June 2003 and September 2005 (n = 3893) at Beijing Anzhen Hospital of Capital University of Medical Science. (Group I, on statins, n = 3361; group II, not on statins, n = 532). To investigate if preoperative statin therapy was independently associated with the reduction in the risk of adverse postoperative outcomes after PCI. Prognostic factors were assessed using Cox multivariate regression analysis to determine if preoperative statin therapy was independently associated with a reduction in the risk of adverse postoperative outcomes.
RESULTS: Our study demonstrated that preoperative statin therapy was not associated with a reduction in risk of mortality and overall MACCE during the hospital stay (0.3% vs. 0.4%; 1.4% vs. 1.2%P > 0.05, respectively).Compared with patients not receiving statins therapy, the hazard ratio for mortality in hospital was 0.738 (95% CI, 0.499-1.211, P = 0.229).
CONCLUSIONS: Preoperative statin therapy did not reduce the risk of mortality and the rates of MACCE during the hospital stay after successful PCI. Cox multivariate regression analysis showed that independent prognostic parameters for mortality were Age, LVEF<50%, Triple vessel CAD, and DM (diabetes mellitus).

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19138238     DOI: 10.1111/j.1365-2710.2008.00954.x

Source DB:  PubMed          Journal:  J Clin Pharm Ther        ISSN: 0269-4727            Impact factor:   2.512


  1 in total

1.  Anti-oxidative stress effect of loading-dose rosuvastatin prior to percutaneous coronary intervention in patients with acute coronary syndrome: a prospective randomized controlled clinical trial.

Authors:  Dong Liang; Qian Zhang; Hexu Yang; Ran Zhang; Wei Yan; Haokao Gao; Jinda Wang; Xiaotian Zhang; Yundai Chen; Feng Cao
Journal:  Clin Drug Investig       Date:  2014-11       Impact factor: 2.859

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.